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A new strategy for assessing selenoprotein function:
siRNA knockdown/knock-in targeting the 39-UTR
MIN-HYUK YOO,1 XUE-MING XU,1 ANTON A. TURANOV,2 BRADLEY A. CARLSON,1
VADIM N. GLADYSHEV,2 and DOLPH L. HATFIELD1
1
Molecular Biology of Selenium Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Institutes of Health,
Bethesda, Maryland 20892, USA
2
Department of Biochemistry, University of Nebraska, Lincoln, Nebraska 68588, USA

ABSTRACT
Selenocysteine insertion into protein in mammalian cells requires RNA elements in the 39-untranslated regions (39-UTRs) of
selenoprotein genes. The occurrence of these conserved sequences should make selenoproteins particularly amenable for
knockdown/knock-in strategies to examine selenoprotein functions. Herein, we utilized the 39-UTR of various selenoproteins to
knock down their expression using siRNAs and then knock in expression using constructs containing mutations within the target
region. Thioredoxin reductase 1 (TR1) knockdown in a mouse kidney cell line resulted in the cells growing about 10% more
slowly, being more sensitive to UV radiation, and having increased apoptosis in response to UV than control cells. The
knockdown cells transfected with a construct encoding the wild-type TR1 gene and having mutations in the sequences targeted
by siRNA restored TR1 expression and catalytic activity, rendered the knockdown cells less sensitive to UV, and protected the
cells against apoptosis. We also applied this technique to other selenoproteins, selenophosphate synthetase 2 and glutathione
peroxidase 1, and found that mRNA and protein levels were restored following transfection of knockdown cells with the
corresponding knock-in constructs. In addition to important new insights into the functions of key mammalian selenoproteins,
the data suggest that the RNAi-based knock-in technology could distinguish phenotypes due to off-targeting and provide a new
method for examining many of the subtleties of selenoprotein function not available using RNAi technology alone.
Keywords: glutathione peroxidase 1; knockdown/knock-in; siRNA; selenophosphate synthetase 2; thioredoxin reductase 1

INTRODUCTION
The targeted removal of protein expression using RNAi
technology has become an extremely powerful tool for
studying protein function (e.g., see Hannon 2002; Novina
and Sharp 2004). However, a serious deficiency in this
technology has been that it could only achieve a decreased
expression of a targeted gene product, limiting its application for an in-depth analysis of protein function. To
overcome this deficiency, several laboratories have developed gene replacement strategies that involve different
approaches in developing knockdown (targeting) and
knock-in (replacement) vectors. For example, silent mutations in the knock-in vector that take advantage of the
genetic code’s degeneracy have been used to circumvent
the knockdown vector (Kim and Rossi 2003; Jiang and
Reprint requests to: Dolph L. Hatfield, Molecular Biology of Selenium
Section, Laboratory of Cancer Prevention, Center for Cancer Research,
Building 37, Room 6032, National Institutes of Health, Bethesda, MD
20892, USA; e-mail: hatfield@mail.nih.gov; fax: (301) 435-4957.
Article published online ahead of print. Article and publication date are
at http://www.rnajournal.org/cgi/doi/10.1261/rna.533007.

Price 2004; Kiang et al. 2005). Species variations in gene
sequences between the knockdown, host protein and the
knock-in, homologous (from a different species with
a varying sequence in the target site) protein have also
been used in gene replacement strategy (Puthenveedu
and Linstedt 2004; Unwalla et al. 2006; Yu et al. 2006).
Other approaches such as ‘‘differential RNA interference’’
(Laatsch et al. 2004) and simultaneous microinjection of
knockdown/knock-in RNAs into Xenopus oocytes (Jallow
et al. 2004) have also been used as gene replacement strategies. It should also be noted that replacement of protein
expression in mammalian cells by knocking in mRNA
synthesis following its knockout is an established method
of studying protein function in the absence of the host
endogenous protein, but this approach requires the initial
generation of knockout and transgenic animals and is
difficult to apply to essential genes (e.g., see Carlson et al.
2005). The ability to combine RNAi-based knockdown and
knock-in approaches is extremely useful and is far simpler
than gene replacement studies involving mouse models.
A unique feature of the mRNAs encoding selenocysteine
(Sec)-containing proteins is that they require a stem–loop
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structure known as a Sec insertion sequence (SECIS)
element for insertion of Sec into the nascent protein in
response to a UGA codon (Low and Berry 1996). SECIS
elements are located in the 39-untranslated region (39UTR) of eukaryotic selenoprotein mRNAs. The highly
developed 39-UTR affords an opportunity of knocking
down and knocking in their expression without involving
the coding region. There are 25 known selenoproteins in
humans and 24 in rodents (Kryukov et al. 2003), and these
proteins have diverse cellular functions, most of which are
unknown. Furthermore, there has been considerable interest in this unique, selenium-containing class of proteins in
recent years as these proteins are thought to be largely
responsible for the many health benefits attributed to the
trace element selenium. For example, selenoproteins have
roles in cancer and heart disease prevention, in viral
inhibition, and roles in development, male reproduction,
and slowing the aging process (Hatfield et al. 2006).
Therefore, the development of simple strategies to elucidate
their functions is important to providing a better understanding of the role of selenium in health.
Among the 24 selenoproteins in rodents (Kryukov et al.
2003), there are three mammalian thioredoxin reductases,
of which one, thioredoxin reductase 1 (TR1), is an essential
Sec-containing oxidoreductase that controls the redox state
of cytosolic thioredoxin and is one of the major redox
regulators in mammalian cells (Mustacich and Powis 2000;
Rundlof and Arner 2004). Herein, we used this protein as a
model in developing a siRNA knockdown-mRNA knock-in
strategy for studying selenoprotein function. We then
applied this technique to other selenoproteins, selenophosphate synthetase 2 (SPS2) and glutathione peroxidase 1

(GPx1), to demonstrate that this approach could have wide
use in studying selenoprotein function.
RESULTS
siRNA constructs and TR1 mRNA knockdown
Four siRNA constructs targeting the 39-UTR of mouse
TR1, designated siTR1-1–4, were prepared. TCMK-1 cells
were transiently transfected with each construct and with
the pU6-m3 control construct. The resulting transfected
cells were labeled with 75Se to evaluate their ability to knock
down TR1 expression. siTR1-3 and siTR1-4, which targeted
sites downstream of the SECIS element, were effective in
down-regulating TR1 expression, whereas the other two
constructs that targeted sites upstream of the SECIS
element were ineffective (Fig. 1A).
TMCK-1 cells were then stably transfected with the siTR13, siTR1-4, or control construct and the levels of TR1 mRNA
examined by Northern blotting (Fig. 1B). TR1 mRNA levels
were substantially reduced in both siTR1 transfected cell
lines compared to cells transfected with the control construct. It should be noted that TMCK-1 cells, stably transfected with the siTR1-3 construct, grew z10% more slowly
than their control cell counterpart, but z15%–20% faster
than cells that were transfected with the siTR1-4 construct
(data not shown). The siTR1-3 construct was, therefore,
used in all subsequent experiments. siTR1-3 transfected cells
and control cells were then labeled with 75Se. Knockdown of
TR1 mRNA by siTR1-3 resulted in the virtual loss of TR1
expression whereas the expression of other major selenoproteins did not appear to be affected (Fig. 1C).

FIGURE 1. Knockdown of TR1 mRNA and TR1. TMCK-1 cells were transfected with the four TR1 siRNA and control constructs either
transiently (A) or stably (B,C) and the resulting transfected cells labeled with 75Se (A,C) or analyzed by Northern blotting (B) as follows: (A, lane
1), pU6-m3; (lane 2) siTR1-1; (lane 3) siTR1-2; (lane 4) siTR1-3; and (lane 5) siTR1-4. (B, lane 1) pU6-m3; (lane 2) siTR1-3; and (lane 3) siTR14. (C, lane 1) pU6-m3; (lane 2) siTR1-3; and (lane 3) siTR1-4. Major selenoproteins are indicated on the right side and molecular weight markers
on the left side of A and C, and migration of 18S and 28S ribosomal RNAs, used as loading controls, are indicated on the right side of the lower
portion in B.
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It should be noted that GPx1, GPx4, and possibly Sep15,
appeared to be slightly enriched in the TR1 knockdown
cells relative to control cells transiently transfected with
siTR1-3 and siTR1-4 (see Fig. 1A), but a similar enrichment
was not observed in the corresponding stably transfected
cells (see Fig. 1C). This difference in selenoprotein synthesis
may be due, at least in part, to the fact that stably transfected cells have a longer time span to adjust to selenoprotein metabolism in response to TR1 knockdown than
transiently transfected cells. Furthermore, the loss of the
more abundantly expressed TR1 may result in greater
accessibility of other selenoprotein mRNAs to the protein
synthesis machinery in the shorter time span found in
transiently transfected cells. However, a similar situation
may not exist in stably transfected cells due to adjustment
of the protein synthesis machinery in maintaining the
expression of selenoproteins at their required levels for
meeting cellular needs.
Characteristics of TR1 knockdown cells
Phenotypic changes between control and transfected cell
lines were initially tested by examining their responses to
UV irradiation. Normally, mammalian cells are treated
with 50–100 J/m2 to induce apoptosis, but we exposed
TMCK-1 cells stably transfected with the siTR1-3 or
control constructs to less than half this amount of radiation

(30 J/m2). UV irradiation was selected as a means of
examining TR1 function since UV induces reaction oxygen
species (ROS) in cells and TR1 is one of the major
antioxidants that protects cells against ROS by maintaining
thioredoxin in the reduced state. The siTR1-3, TR1
knockdown cells were more sensitive to UV irradiation
than the control cells at this level of exposure. Less than
50% of the TR1 knockdown cells were recovered upon UV
irradiation compared to control cells (Fig. 2A). Cleavage of
caspase-3 is an indication of apoptosis and JNK1 and JNK2
are major kinases involved in the apoptosis pathway. We
therefore examined the cleavage of caspase-3 and the
phosphorylation of JNK1/2 by Western blot analysis in
cells either exposed or unexposed to UV irradiation (Fig.
2B,C, respectively). Untreated control and siTR1-3 cells did
not show any cleavage of caspase-3, and control cells
treated with UV irradiation had only a slightly visible
cleaved caspase-3 band, whereas the siTR1-3 UV-treated
cells manifested a clearly visible cleaved caspase-3 (Fig. 2B).
Phosphorylation of JNK1/2 was examined in control
pU6-m3 and siTR1-3 transfected cells at 0, 10, and 30 min
after exposure to UV (Fig. 2C). Control cells manifested
phosphorylation of JNKs at 30 min after exposure, but the
level was lower than that observed with siTR1-3 transfected
cells (designated P-JNK1 in Fig. 2C). Furthermore, both
JNK1 and JNK2 were phosphorylated at 30 min in siTR1-3
transfected cells (designated P-JNK2 in Fig. 2C).

FIGURE 2. UV sensitivity of the siTR1-3 cells. (A) Viability of cells was determined by counting cell numbers after harvesting 24 h following UV
irradiation (see Materials and Methods) of pU6-m3 control cells and siTR1-3 stably transfected cells. (B) Cleavage of caspase-3 was determined by
Western blot analysis in cell lysates of UV-irradiated cells: (lanes 1,2) untreated and UV treated pU6-m3 transfected cells; (lanes 3,4) untreated
and UV treated siTR1-3 transfected cells, respectively. (C) Phosphorylation of JNK (designated P-JNK1/2) was monitored in pU6-m3 and siTR1-3
cell lysates by Western blot analysis after UV irradiation at 0, 10, and 30 min of pU6-m3 transfected cells (lanes 1–3) and siTR1-3 transfected cells
(lanes 4–6). Total amount of JNK is shown as a quantitative control in the lower panel of C. Molecular weight markers are indicated on the left in
B and C.
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TR1 replacement
TMCK-1 cells that had been stably transfected with the
siTR1-3 construct were transiently transfected with the
expression vectors encoding either the wild-type (TR1wt)
or mutant (siTR1-3m or siTR1-3mD) mRNAs. Initially,
the TR1 mRNA levels were examined in each cell line. Cells
stably transfected with pU6-m3 or siTR1-3 were used as
controls showing that TR1 mRNA was expressed (Fig. 3A,
lane 1) and knocked down (Fig. 3A, lane 2) when these
cell lines were transfected transiently. siTR1-3 cells transiently transfected with the TR1wt construct had substantially reduced amounts of TR1 mRNA (Fig. 3A, lane
3), while those transfected with TR1-3m appeared to
express TR1 mRNA, but the Northern band was smeared,
suggesting that it was degraded (Fig. 3A, lane 4). Cells
transiently transfected with the siTR1-3mD construct that
encoded, in addition to the mutations in the siTR1 target
site, a deletion of the ARE region (Fig. 3A, lane 5) expressed
TR1 mRNA.

The above cell lines were labeled with 75Se. The pU6-m3
control cell line and that transiently transfected with siTR13mD had the highest TR1 synthesis (Fig. 3B). Comparison
of Figure 3B, lanes 4 and 5, demonstrate the requirement
for the ARE deletion in TR1 mRNA for generating an
efficient knock-in construct (Gasdaska et al. 1999). The
ARE region in the 39-UTR of TR1 mRNA is known to
regulate mRNA stability, and deletion of this region results
in increased mRNA stability and enhanced protein expression (Gasdaska et al. 1999).

Characteristics of TR1 replacement cells
TR1 activities and expression levels were determined in
knock-in and control cells by direct assay and Western blot
analysis (Fig. 3C,D, respectively). The knock-in cells manifested higher TR activity than their counterparts transiently transfected with the pcDNA3.1 vector, demonstrating
that TR1 had been replaced in the knock-in cells (Fig. 3C).

FIGURE 3. TR1 replacement. Cells that were stably transfected with pU6-m3 or siTR1-3 constructs were transiently transfected with the
expression vector pcDNA3.1 or the expression vector encoding TR1wt, TR1-3m, or TR1-3mD and the resulting cells analyzed as follows: (A)
Northern blotting of RNA extracts to determine TR1 mRNA levels (upper panel): (lane 1) pU6-m3 + pcDNA3.1; (lane 2) siTR1-3 + pcDNA3.1;
(lane 3) siTR1-3 + TR1wt; (lane 4) siTR1-3 + TR1-3m; and (lane 5) siTR1-3 + TR1-3mD. Ribosomal 18S and 28S RNA are shown as loading
controls (lower panel); (B) Expression of 75Se-selenoproteins in extracts from labeled cells: (lane 1) pU6-m3 + pcDNA3.1; (lane 2) siTR1-3 +
pcDNA3.1; (lane 3) siTR1-3 + TR1wt; (lane 4) siTR1-3 + TR1-3m; and (lane 5) siTR1-3 + TR1-3mD. Molecular weight markers and
selenoprotein designations are indicated as given in the legend of Figure 1; (C) Measurement of TR1 activity in cell extracts from pU6-m3 +
pcDNA3.1, pU6-m3 + TR1-3mD, siTR1-3 + pcDNA3.1, and siTR1-3 + TR1-3mD are as shown, and the data are the mean 6 S.D. (n = 3); (D)
Western blotting of protein extracts from pU6-m3 + pcDNA3.1, pU6-m3 + TR1-3mD, siTR1-3 + pcDNA3.1, and siTR1-3 + TR1-3mD assessing
the presence of TR1 (upper panel) and using b-tubulin as an internal control (lower panel).
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The ‘‘background’’ activity in the TR1 knockdown cells
transiently transfected with pcDNA3.1 vector is most likely
due to TR3 activity and possibly residual TR1 activity, as the
enzymatic assay for TR does not distinguish between the
different homologs. The amount of TR activity was similar
in the pU6-m3 control cells as in the knock-in cells, but
was >2.5-fold higher in the pU6-m3 cells transiently transfected with the expression TR1wt construct. Western blot
analysis confirmed the expression of TR1 in the knock-in
cells and reflected the amount of TR1 in each cell line that
was expected from the enzymatic activity assays (see Fig. 3D).
UV-mediated phosphorylation levels of JNK1 and JNK2
in cells stably transfected with the knockdown vector and
transiently transfected with either the pcDNA3.1 vector or
the knock-in construct were examined. The bands corresponding to phosphorylated JNK1 and JNK2 appeared
more intense in the UV-treated cells transiently transfected
with pcDNA3.1 than the knock-in cell line, suggesting that
TR1 replacement at least partially rescued the cells from
UV-mediated apoptosis (Fig. 4A). The intensities of phosphorylated JNK1 and JNK2 are shown relative to the
intensities of phosphorylated JNK1 and JNK2 observed in
UV-treated control cells when the latter two bands were
assigned a value of 1.0 (Fig. 4B), which clearly show that
after TR1 knock-in, JNK phosphorylation was decreased.
Application of the knockdown/knock-in strategy
to other selenoproteins
The strategy of targeting the knockdown of TR1 within its
39-UTR followed by its replacement worked exceptionally
well with this selenoprotein. To determine if this approach
can be applied to other selenoproteins, we examined GPx1,
which is one of the most widely studied selenoproteins
(e.g., see Sunde 2006), and SPS2, which is responsible for
generating the active selenium donor, selenophosphate, for
Sec synthesis in eukaryotes (see Xu et al. 2007b, and
references therein). The targeting site within the 39-UTR
of GPx1 mRNA that was most effective in its knockdown
(see Materials and Methods) was used for further study.
NIH3T3 cells were stably transfected with the siGPx1
construct or the pU6-m3 control construct (Fig. 5A,B).
siGPx1 stably transfected cells were then transiently transfected with constructs containing either the empty vector
(pcDNA), the wild-type GPx1 gene (GPx1 wt), or the GPx1
gene encoding the mutant targeted site (GPx1-in) and the
mRNA levels analyzed by Northern blotting (Fig. 5A, lanes
2–4, respectively). GPx1 mRNA was knocked down efficiently as compared to cells encoding the pU6-m3 control
construct (Fig. 5A, lanes 1 and 2), and the level of
knockdown was the same as that in GPx1 mRNA knockdown observed in cells stably transfected with siGPx1
construct alone (data not shown). Cells transiently transfected with the GPx1 wild-type construct showed that the
GPx1 mRNA was smeared and reduced compared to cells

FIGURE 4. UV sensitivity of TR1 replacement cells. (A) Cells stably
transfected with siTR1-3 constructs were transiently transfected with
the control (pcDNA3.1) or TR1 expression vector (TR1-3mD), and
24 h after exposure to UV irradiation, phosphorylation of JNK1 and
JNK2 (designated P-JNK1 and P-JNK2) were analyzed by Western
blotting (upper panel). (Lanes 1,2) siTR1-3 + pcDNA3.1 untreated
and treated with UV irradiation, respectively; (lanes 3,4) siTR1-3 +
TR1-3mD untreated and treated with UV irradiation, respectively.
Total amounts of JNK are shown as a quantitative control in the lower
panel. (B) Intensities of bands relative to P-JNK1 and P-JNK2 in
siTR1-3 + pcDNA3.1 UV-treated cells when the latter two bands were
given a value of 1.0 and the data plotted as shown. Band intensities
were assessed using the ImageQuant program.

transfected with the control construct (Fig. 5A, lanes 1 and
3), while cells transiently transfected with the mutant GPx1
construct manifested a considerable enrichment in GPx1
mRNA (Fig. 5A, lane 4). Labeling each of the cell lines with
75
Se and subsequent electrophoresis of protein extracts
showed that GPx1 was poorly expressed in GPx1 mRNA
knockdown cells (Fig. 5B, cf. lanes 2,3 and lane 1), while
GPx1 levels were markedly enriched in the knock-in cells
compared to control cells (Fig. 5B, lanes 4 and 1).
The Tet-on system was used for exploring whether SPS2
could be a candidate for the knockdown/knock-in technology. NIH3T3 cells stably transfected with the Tet-siSPS2
construct were grown in the presence or absence of
doxycycline. The knockdown vector expressed in the
presence of doxycycline targeted the removal of SPS2
mRNA (data not shown). NIH3T3 cells stably transfected
with the SPS2 knockdown construct were then transiently
transfected with either the wild-type SPS2 construct (SPS2
wt), the knock-in SPS2 construct (SPS2 in), or the control
www.rnajournal.org
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FIGURE 5. Knockdown/knock-in of GPx1 and SPS2. In A and B, NIH3T3 cells were stably
transfected with the pU6-m3 control construct or the siGPx1 construct and then transiently
transfected with the pcDNA3.1 expression vector or the expression vector encoding GPx1 wildtype gene (GPx1 wt) or GPx1 knock-in gene (GPx1 in) and the cells analyzed by (A) Northern
blotting of RNA extracts for GPx1 mRNA: (lane 1) pU6-m3 + pcDNA3.1; (lane 2) siGPx1 +
pcDNA3.1; (lane 3) siGPx1 + GPx1 wt; and (lane 4) siGPx1 + GPx1-in (upper panel), and (B)
labeling of cells with 75Se and subsequent electrophoresis of protein extracts. Lanes 1–4 are
the same as those given in A above. In C and D, NIH3T3 cells were stably transfected with the
Tet-on U6 control construct or the Tet-siSPS2 construct and grown in the presence or absence
of 5 mg/uL doxycycline for 3 d to induce knockdown SPS2, then transiently transfected with
pTriEX expression vector or the expression vector encoding SPS2 wild-type gene (SPS2 wt) or
SPS2 knock-in gene (SPS2 in) and the cells analyzed by (C) Northern blot analysis of RNA
extracts for SPS2 mRNA: lanes 1 and 2 contain extracts of Tet-siSPS2 transfected with expression
vector in the presence or absence of doxycycline; lanes 3 and 4 contain extracts of Tet-siSPS2
transfected with SPS2 wild-type expressing vector in the presence or absence of doxycycline;
lanes 5 and 6 contain extracts of Tet-siSPS2 transfected with the SPS2 wild-type expressing vector
in the presence or absence of doxycycline (upper panel) and (D) labeling cells with 75Se and
subsequent gel electrophoresis of protein extracts. Lanes 1–6 are the same cell lines as those given
in C above. The 75Se-labeled panel shows TR1 and the overexpressed SPS2 bands that have
similar migrations except SPS2 runs slightly lower. The expression of SPS2 was confirmed by
Western blot analysis using antibodies to His-tag of the ectopic SPS2 protein (lower panel).
18S and 28S ribosomal RNAs are shown as loading controls in the lower panels of A and C.

construct (pTriEX), and grown with or without doxycycline. SPS2 mRNA was examined in cell extracts by
Northern blotting (Fig. 5C). Clearly, SPS2 was restored in
cells carrying the knock-in construct (Fig. 5C, cf. lanes 5,6
and lanes 1,2), but not in cells carrying the SPS2 wt
construct grown in the presence of doxycycline (Fig. 5C,
lane 4). As expected, cells carrying the SPS2 wt construct
grown in the absence of doxycycline had SPS2 mRNA.
SPS2 was overexpressed in these cells and therefore was
detectable by 75Se labeling. The SPS2 construct contained a
His-tag at its carboxy terminus and therefore it migrated
926
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slightly slower on polyacrylamide gels
compared to the corresponding, untagged
protein. TR1 and SPS2 migrate at
approximately the same position on
polyacrylamide gels as shown in Figure
5D. As it was difficult to distinguish
SPS2 expression independently of TR1
expression in 75Se-labeled cells due to
their close migration on gels, the
expression of SPS2 was further examined by Western blot analysis using
antibodies against the His-tag (Fig. 5D,
lower panel). SPS2 was clearly expressed in cells carrying the knock-in
construct (Fig. 5D, lanes 5 and 6)
and in cells carrying the SPS2 wt
construct grown in the absence of
doxycycline, but poorly expressed in
corresponding cells grown in the
presence of doxycycline (Fig. 5D, lanes
3 and 4, respectively). The virtual loss
of selenoprotein expression due to the
knockdown of SPS2, as assessed by
75
Se labeling (Fig. 5D, lane 2), would be
expected, as its removal results in a loss
of selenophosphate production, which
is essential to selenoprotein synthesis
(Xu et al. 2007a). It should be noted
that in order to visualize the effect
of siSPS2 on SPS2 expression, polyacrylamide gels containing labeled selenoproteins were run much longer to partially
separate TR1 and SPS2, which migrate
at similar positions. As a consequence,
the lower molecular weight selenoproteins ran off the gel (see Fig. 5D).
However, the effect of SPS2 knockdown
on the entire population of selenoproteins following their labeling with
75
Se and separation on polyacrylamide
gels can be seen in studies published
elsewhere (Xu et al. 2007a).

DISCUSSION
A major limitation in using RNAi technology to knock
down protein expression has been that the resulting
phenotype and protein function are assessed solely on the
basis of protein loss. This approach does not permit an indepth examination of the characteristics of protein function, for example, by mutational analyses. Assessing protein
function by introducing transgenes encoding mutant forms
of the protein of interest into a cell also has the limitation
of maintaining the host wild-type protein. However, using

Selenoprotein knockdown/knock-in strategy

RNAi technology to initially target knockdown of a host
protein and then knock-in with a mutant or wild-type
protein permits analyses of other aspects of protein
function without interference from the host protein as
discussed in the Introduction. Selenoproteins would
seem particularly amenable to lending themselves to an
approach of knockdown/knock-in technology to study
their function, as they possess highly developed 39-UTRs
that can be targeted for knockdown of selenoprotein
mRNA without affecting the open reading frame of the
coding sequence. We have developed such a technology
specifically designed for knockdown of selenoproteins by
targeting the 39-UTR. Efficient knockdown of mRNA and
protein expression of TR1 were carried out by using two
siRNAs that targeted sites downstream of the SECIS
element. It is not surprising that TCMK-1 cells stably
transfected when these siRNA grew slower than the
corresponding control cells carrying wild-type TR1 since
TR1 is an essential selenoprotein.
Cells in which the TR1 was stably knocked down were
found to be about twice as sensitive to UV irradiation as
control cells containing wild-type TR1 activity. In addition,
the loss of TR1 expression resulted in cells showing greater
signs of UV-mediated apoptosis as evidenced by cleavage of
caspase-3 and an enhanced phosphorylation of JNK1/2. We
also previously used RNAi technology to knock down TR1
expression in a mouse lung cancer cell line (LLC1), which
reversed several of the malignant phenotypes, including
reducing tumor progression and metastasis (Yoo et al.
2006). The alterations in phenotype of TCMK-1 as a result
of reduction of TR1 described herein, however, are different from those observed in the LLC1 cell line.
TCMK-1 cells that were stably transfected with the
knockdown construct were further transiently transfected
with the expression knock-in construct, TR1-3mD. Efficient TR1 replacement required, in addition to the mutations at the target site, deletion of the ARE region near the
39 terminus of the 39-UTR. The fact that removal of the
ARE region is essential for TR1 knock-in was anticipated,
since it has been shown that deletion of this region is
essential for TR1 overexpression (Gasdaska et al. 1999).
Although the level of transient transfection in TR1 replacement cells was z40%, the amount of TR1 was similar to
that observed in control cells as determined by enzymatic
activity and Western blotting, but slightly higher as
determined by 75Se labeling. The higher TR1 expression
levels in cells with only z40% transfection levels is most
certainly due to the overexpression of TR1, whose gene was
cloned into the pcDNA3.1 mammalian expression vector.
UV sensitivity of the TR1 replacement cells showed that
cells stably transfected with the knockdown construct and
transiently transfected with TR1-3mD were more resistant
than their counterpart cells transiently transfected with
the pcDNA3.1 vector, suggesting that TR1 replacement
restored UV resistance.

The UGA Sec codon in TR1 is the penultimate codeword
in the corresponding mRNA. It is possible that the location
of the UGA codon in TR1 would make this selenoprotein
amenable to knockdown/knock-in technology whereas the
UGA Sec codons in most other selenoproteins, which are
located elsewhere in sequences, could be less favorable to
application of such technology. We therefore examined
two other mammalian selenoproteins, GPx1 and SPS2, that
contain their Sec residues more proximal to the aminoterminal regions. These two selenoproteins were also
selected for study because GPx1 is one of the most widely
studied selenoproteins (e.g., see Sunde 2006), and SPS2
plays an essential role in Sec biosynthesis by generating
selenophosphate, which is the selenium donor for this
pathway (see Xu et al. 2007a,b, and references therein).
Targeting sites in the 39-UTR of both these selenoproteins
that effectively knocked down both mRNAs, and the
corresponding proteins, were found and further experimentally verified in the knockdown/knock-in procedure.
One of the major criticisms of RNAi technology in
assessing the phenotypes associated with knocking down
protein expression has been that it may result in off-targeting,
wherein another RNA is also affected in addition to the
targeted mRNA (Birmingham et al. 2006). Targeting more
than a single site, as we have done with the three selenoproteins examined in the present study, substantially decreases
the likelihood of off-targeting. The knockdown/knock-in
approach, however, eliminates this possibility altogether
and should be extremely useful for phenotypic analyses.
Knockdown/knock-in technology provides a new
approach to examining many subtleties involving selenoprotein function. For example, a more detailed analyses of
Sec UGA codon–nucleotide context (McCaughan et al.
1995), Sec UGA codon–SECIS element association
(Korotkov et al. 2002), and a recently identified novel
RNA structure present downstream of Sec UGA codons in
certain selenoprotein mRNAs (Howard et al. 2005), could
be more readily examined by a knockdown/knock-in
strategy. Similarly, this approach could presumably be
adapted to many other classes of proteins. Clearly, utilizing
target sites in the 39-UTR for developing knockdown/
knock-in strategies has the distinct advantage of avoiding
the base changes within the open reading frame that, even
though they may not cause an amino acid change, may
result in dramatically altering expression of the resulting
protein (Kimchi-Sarfaty et al. 2007).
MATERIALS AND METHODS
Materials
75

Se (specific activity, 1000 Ci/mmol) was obtained from the
Research Reactor Facility, University of Missouri, Columbia,
Missouri, and [a-32P]CTP (specific activity 6000 Ci/mmol) from
Perkin-Elmer. Primers containing a loop for siRNA hairpin
www.rnajournal.org
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formation, sense, and anti-sense sequences corresponding to the
target regions in mouse TR1, GPx1, and SPS2 were prepared by
Sigma Genosis, and were designed to have BamHI and HindIII
restriction sites at the 59 and 39 ends, respectively. pcDNA3.1
mammalian expression vector was purchased from Invitrogen Life
Technologies and siRNA vector pSilencer 2.1-U6 Hygro from
Ambion, Inc. Antibodies against JNK, phospho-JNK and caspase3, and HRP-conjugated secondary antibodies were purchased
from Cell Signaling Technology and anti-His antibodies from
Qiagen. Mouse kidney cells and mouse fibroblast, designated
TCMK-1 and NIH3T3, were obtained from the American Type
Culture Collection (ATCC). All other reagents were commercial
products of the highest grade available.

Knockdown of TR1, GPx1, and SPS2
pU6-m3 was prepared (Xu et al. 2007a) and used as a cloning
vector for siTR1 targeting sequences and to transfect TCMK-1
cells as a control vector. The 39-UTR of mouse TR1, GPx1, and
SPS2 mRNAs (GenBank Accession Numbers NM_015762, NM
008160, and NM 009266, respectively) was surveyed using the
diDESIGN program (Dharmacon, Inc.). Four candidate target
regions within the 39-UTR of TR1 were selected that spanned
nucleotides 1721–1741, 1760–1780, 1993–2014, and 2480–2500,
respectively. Sense–anti-sense oligonucleotides, designed according to the instructions detailed in the cloning manual of the
pSilencer 2.1U6 Hygro vector, were annealed and inserted into
the BamHI–HindIII cloning sites in pU6-m3. The sequences of the
resulting constructs, designated siTR1-1, siTR1-2, siTR1-3, and
siTR1-4, were confirmed by sequencing.
For knocking down GPx1, three candidate siRNA targeting sites
within the 39-UTR were selected that spanned nucleotides 702–720,
788–806, and 803–821, and the corresponding knockdown constructs were prepared in the same manner as the TR1 knockdown
constructs. Northern blot and 75Se-labeling analysis of NIH3T3
cells stably transfected cells with the siRNA constructs demonstrated that the targeting site spanning nucleotides 803–821 was
the most effective in knocking down GPx1, and this knockdown
construct was used in the present studies as described in the Results.
To knock down SPS2, the doxycyclin-inducible Tet-on U6
construct was prepared using the pU6-m4 Hygro vector (Xu
et al. 2007a) as backbone. Two O2-type Tet operators were then
generated that flanked the TATA box of the U6 promoter (Lin
et al. 2004) using the QuikChange II Site-Directed Mutagenesis
Kits, and the resulting vector was designated pU6-TetO4m4.
The SPS2 siRNA constructs of pU6-TetO4m4 were prepared as
described (Xu et al. 2007a). Of the three separate 19 nucleotide (nt)
siRNA target sequences generated within the 39-UTR of SPS2, Northern blot analysis showed that targeting mRNA spanning1821–1839
was the most effective at knocking down the corresponding mRNA
and it was used in subsequent experiments. In SPS2 knockdown
and knock-in experiments, cells stably transfected with SPS2 or
control siRNA constructs were induced with 5 mg/mL doxycycline
for 3 d, then labeled with 75Se or harvested for RNA preparation.

restriction sites to knock in TR1. Mutations in the siRNA target
region involving bases 1993–2014 were introduced by PCR using
mutant primers, siTR1-3m forward, 59-gtcttagtctcaaggtacctatgtc
taatgtc-39, and siTR1-3m reverse, 59-gacattagacataggtaccttgagactaa
gac-39, where the bold, lowercase letters indicate mutated regions.
Two partial TR1 fragments encompassing bases 15–2014 (from the
59-UTR to the siRNA target region) and 1993–3310 (from the siRNA
target region to the end of the 39-UTR) were synthesized with mutant
primers by PCR, and the full-length TR1 gene was synthesized
by annealing the two partial fragments and extending both ends
using Pfx DNA polymerase. The product was cloned into
pcDNA3.1 (the resulting mutant construct was designated TR13m). The AU-rich mRNA instability element (ARE) located in the
39-UTR of TR1 (bases 2407–3310; Gasdaska et al. 1999) was
deleted using BlpI and XhoI restriction sites to enhance the
stability of TR1 mRNA, and the resulting mutant construct was
designated TR1-3mD.
To knock in GPx1 and SPS2, mutations in the target regions in
GPx1 (nucleotides 803–821, 59-gcgagagatgggttcaata-39) and SPS2
(nucleotides 1821–1839, 59-caagagttgccacaggata-39) were introduced by PCR where the bold, lowercase letters indicate mutated
nucleotides.

Mammalian cell culture, transfection, transient
transfection efficiencies, and UV irradiation
TCMK-1 or NIH3T3 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum and antibiotic-antimycotic solution at 37°C as described in
ATCC’s product description packet. Cells were maintained in
growth phase by splitting every 3 d using Trypsin-EDTA. Stably
transfected siTR1-3 (knockdown) and stably transfected pU6-m3
(control) cells were prepared by transfecting with the corresponding constructs using Lipofectamine 2000 and then selecting cells
in the presence of 500 mg/mL of hygromycin B. In addition, both
these stably transfected cell lines were transiently transfected with
the control (pcDNA3.1), wild-type (TR1wt), and mutant (siTR13m and siTR1-3mD) constructs. Efficiency of transient transfection was measured by cotransfecting GFP expression construct
with the pcDNA3.1 or TR1-m3D constructs, counting GFP
expressing cells under a fluorescent microscope, and was found
to be z40% in each case (data not shown).
To assess the UV sensitivity of each cell line, 1.0 3 106 cells were
seeded onto a 60 mm culture dish, and, in the case of transiently
transfected cells, the cells were seeded 24 h after transfection, and
each cell line incubated 24 h before irradiating with UV (30 J/m2);
UV-irradiated cells then harvested at preselected times (see legends to
figures) for assessing JNK phosphorylation and caspase-3 cleavage.
Cells were harvested and counted using the Trypan-blue exclusion
method (Freshney 1987) or assessed for JNK phosphorylation and
caspase-3 cleavage by Western blotting 24 h after irradiation. The
relative amounts of JNK phosphorylation following Western blot
analysis were quantitated using the ImageQuant program.

Replacement of TR1, GPx1, and SPS2

Northern and Western blot analyses, 75Se labeling
of cells, and assay for thioredoxin reductase activity

The entire TR1 gene containing both the 59- and 39-UTRs was
amplified by RT-PCR of TCMK-1 total RNA and cloned into the
pcDNA3.1 mammalian expression vector using the HindIII and XhoI

Total RNA was prepared from cultured cells, 12 mg of total RNA
electrophoresed and transferred, membranes hybridized with probes for
TR1, GPx1, or SPS2 (prepared by random labeling with [a-32P]CTP),
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washed, and exposed to a PhosphorImager (Molecular Dynamics)
as described (Moustafa et al. 1998; Carlson et al. 2005).
Cells were washed in cold PBS, lysates prepared, 30 mg of each
protein sample electrophoresed, the separated proteins transferred,
and the membrane incubated initially with primary antibody (antiphospho-JNK, anti-JNK, anti-caspase-3, or anti-His) and then with
HRP-conjugated secondary antibody and exposed to X-ray film as
described (Moustafa et al. 1998; Carlson et al. 2005).
Cells were seeded onto a six-well plate (3 3 105 cells/well),
incubated 18 h, then labeled with 40 mCi of 75Se for 24 h, and
harvested and lysed as described (Moustafa et al. 1998; Carlson
et al. 2005). Forty micrograms of each sample were electrophoresed, proteins stained with Coomassie Blue, and the gel dried
and exposed to a PhosphorImager (Molecular Dynamics) as
described (Moustafa et al. 1998; Carlson et al. 2005).
The specific enzymatic activity of TR in cell extracts was
determined using the insulin assay as described (Arner et al. 1999).
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